Researchers say an experimental mRNA vaccine has shown encouraging early results in a phase 1 trial, with the potential to target more than one type of cancer. The study, reported by Reuters, suggests the approach could eventually broaden the use of personalized immunotherapy beyond a single tumor type.

According to the report, participants in the early trial produced strong immune responses after receiving the vaccine, while side effects were described as manageable. That makes the treatment an important signal for a field that has long been searching for more flexible ways to train the immune system to recognize cancer cells.

The findings are still preliminary. Phase 1 trials are designed primarily to assess safety and dosing, not to prove that a treatment works at scale. Even so, the results may help researchers refine the technology and move it into larger studies that can test whether the vaccine can improve outcomes for patients with different cancers.

If later trials confirm the early data, the platform could mark a meaningful step forward for cancer immunotherapy. For now, the work remains experimental, but it adds to growing interest in mRNA-based treatments beyond infectious disease.